The University of Pennsylvania (Penn) Cancer Research Training Program is designed to identify and train the next generation of outstanding investigators focused on the problem of human cancer. The Program provides the protected time, resources, educational experience, mentorship and environment necessary to achieve this goal, as has been demonstrated throughout the past 25 consecutive years of funding. Traditionally focused on emerging physician-scientists training in medical and/or pediatric oncology, the Program has been highly successful in nurturing these young investigators to productive research careers in basic and clinical cancer research. To meet the increasing demands of our shared translational research mission and the growing size of our fellowship programs, as well as outstanding potential trainees in the ancillary medical, pediatric, surgical and pathology subspecialties, we now propose to increase the number of trainees supported by this program from six to eight. This is timely due to the number of highly qualified applicants to the program that we have not been able to support over the past five years. To support this increased number of trainees, we have carefully reviewed and revised our Steering Committee while maintaining the core leadership, we have newly appointed an external Advisory Committee, and have bolstered our faculty mentors to assure expertise in emerging areas such as immunotherapy, expand diversity and to assure that younger faculty engage in training through co- mentorship opportunities. Thus, the 44 faculty preceptors from the Abramson Cancer Center (ACC) at UPenn were selected from across the translational research spectrum to provide a rich group of potential mentors to all trainees. The modified Training Program will leverage the existing strengths that have been successful in training our physician-scientists, and we have now extensively enhanced our evaluation procedures, reformatted our annual retreat, and retooled our recruitment plans including a broad-based effort to enhance diversity, increasing the likelihood that our trainees will be future international leaders in cancer research

Public Health Relevance

Significant advancement towards preventing and curing human cancer relies on quality investigators dedicated to translational science. The Cancer Research Training Program at the University of Pennsylvania strives to recruit and train the next generation of individuals who will lead the field of cancer research with a focus on impacting patient care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Richman, Sarah A; Nunez-Cruz, Selene; Moghimi, Babak et al. (2018) High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunol Res 6:36-46
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
Bosse, Kristopher R; Raman, Pichai; Zhu, Zhongyu et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:295-309.e12
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Wilson, Melissa A; Guld, Kelly; Galetta, Steven et al. (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4:66
Shah, Nirav N; Casella, Erica; Capozzi, Donna et al. (2016) Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract 12:e71-6
Pauken, Kristen E; Sammons, Morgan A; Odorizzi, Pamela M et al. (2016) Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160-1165
Bosse, Kristopher R; Maris, John M (2016) Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122:20-33

Showing the most recent 10 out of 85 publications